Strategic partnership forms single-source solution for biopharma

10-Jan-2017 - Last updated on 10-Jan-2017 at 18:47 GMT

(Image: CSSi Life Sciences)

CSSi LifeSciences and BioMARC have announced a strategic partnership to provide 'fully cohesive product development and support' for vaccine and biologic development.

CSSi LifeSciences, an industry partner for discovery and commercialization of biologics and vaccines, announced the strategic partnership with the Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC), a nonprofit contract manufacturing service run by Colorado State University.

"The goal of the partnership between CSSi LifeSciences and BioMARC is to provide our clients with the services, resources and solutions needed to help meet their needs for innovation and development programs related to the prevention, management and treatment of infectious diseases," Jim Sergi, president, CSSi LifeSciences, told Outsourcing-Pharma.com.

"Such capabilities focus on development and manufacturing expertise, addressing the tough problems and challenging tasks in this field that do not exist broadly in the biopharma environment," Raymond Goodrich, PhD, Executive Director, Infectious Disease Research Center at BioMarc, added.

The companies' expertise ranges from preclinical testing, to cGMP production and on through late stage clinical trials as well as commercialization.

Dennis Pierro, PhD, Director, BioMARC, told us the benefit to clients is in the "fully cohesive product development support and regulatory guidance," now available as part of the strategic partnership.

The official announcement was made at the CSSi LifeSciences Partnering Forum 2017, which took place yesterday at the J.P. Morgan 35th Annual Healthcare Conference.